Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies

Preventive Medicine

Volumn 53, Issue SUPPL. 1, 2011, Pages

  Tota, Joseph E ^a   Chevarie Davis, Myriam ^a   Richardson, Lyndsay A ^a   DeVries, Maaike ^a   Franco, Eduardo L ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Burden; Cervical cancer; Human papillomavirus; Prevention

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

CANCER MORTALITY; DEVELOPING COUNTRY; EPIDEMIOLOGICAL DATA; GENOTYPE; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; MASS SCREENING; OROPHARYNX CANCER; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VAGINA CANCER; VULVA CANCER; WART VIRUS;

ALPHAPAPILLOMAVIRUS; COST OF ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS;

EID: 80053445327     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2011.08.017     Document Type: Review

References (149)

1. Aral S.O., Peterman T.A. A stratified approach to untangling the behavioral/biomedical outcomes conundrum. Sex. Transm. Dis. 2002, 29(9):530-532. Sep.
2. Arbyn M., Sasieni P., Meijer C.J., et al. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006, 24(Suppl. 3):S378-S389. Aug 31.
3. Arbyn M., Raifu A.O., Weiderpass E., et al. Trends of cervical cancer mortality in the member states of the European Union. Eur. J. Cancer 2009, 45(15):2640-2648. Oct.
4. Arbyn, M., Castellsague, X., de Sanjose, S., et al., in press. Worldwide burden of cervical cancer in 2008. Ann. Oncol. Apr 6 (Electronic publication ahead of print). doi:10.1093/annonc/mdr015.
5. Auvert B., Sobngwi-Tambekou J., Cutler E., et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J. Infect. Dis. 2009, 199(1):14-19. Jan 1.
6. Baldwin S.B., Wallace D.R., Papenfuss M.R., et al. Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex. Transm. Dis. 2004, 31(10):601-607. Oct.
7. Baseman J.G., Koutsky L.A. The epidemiology of human papillomavirus infections. J. Clin. Virol. 2005, 32(Suppl 1):S16-S24. Mar.
8. Bauer H.M., Hildesheim A., Schiffman M.H., et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex. Transm. Dis. 1993, 20(5):274-278. Sep-Oct.
9. Bosch F.X., Manos M.M., Munoz N., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst. 1995, 87(11):796-802. Jun 7.
10. Brotherton J.M., Fridman M., May C.L., et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377(9783):2085-2092. Jun 18.
11. Brown D.R., Kjaer S.K., Sigurdsson K., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26years. J. Infect. Dis. 2009, 199(7):926-935. Apr 1.
12. Bruni L., Diaz M., Castellsague X., et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J. Infect. Dis. 2010, 202(12):1789-1799. Dec 15.
13. Buck C.B., Thompson C.D., Roberts J.N., et al. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2006, 2(7):e69. Jul.
14. Bulkmans N.W., Rozendaal L., Snijders P.J., et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int. J. Cancer 2004, 110(1):94-101. May 20.
15. Bulkmans N.W., Berkhof J., Rozendaal L., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007, 370(9601):1764-1772. Nov 24.
16. Burchell A.N., Richardson H., Mahmud S.M., et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am. J. Epidemiol. 2006, 163(6):534-543. Mar 15.
17. Castellsague X., Bosch F.X., Munoz N., et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N. Engl. J. Med. 2002, 346(15):1105-1112. Apr 11.
18. Castellsague X., Bosch F.X., Munoz N. The male role in cervical cancer. Salud Publica Mex. 2003, 45(Suppl. 3):S345-S353.
19. Castle P.E., Schiffman M., Herrero R., et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J. Infect. Dis. 2005, 191(11):1808-1816. Jun 1.
20. Chaturvedi A.K. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J. Adolesc. Health 2010, 46(4 Suppl.):S20-S26. Apr.
21. Chaturvedi A.K., Myers L., Hammons A.F., et al. Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections. Cancer Epidemiol. Biomarkers Prev. 2005, 14(10):2439-2445. Oct.
22. Chaturvedi A.K., Engels E.A., Anderson W.F., et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J. Clin. Oncol. 2008, 26(4):612-619. Feb 1.
23. Chin-Hong P.V., Vittinghoff E., Cranston R.D., et al. Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J. Infect. Dis. 2004, 190(12):2070-2076. Dec 15.
24. Clifford G.M., Gallus S., Herrero R., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366(9490):991-998. Sep 17-23.
25. Cotton S.C., Sharp L., Seth R., et al. Lifestyle and socio-demographic factors associated with high-risk HPV infection in UK women. Br. J. Cancer 2007, 97(1):133-139. Jul 2.
26. Cuzick J., Clavel C., Petry K.U., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 2006, 119(5):1095-1101. Sep 1.
27. de Sanjose S., Diaz M., Castellsague X., et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect. Dis. 2007, 7(7):453-459. Jul.
28. de Sanjose S., Quint W.G., Alemany L., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010, 11(11):1048-1056. Nov.
29. Denny L., Quinn M., Sankaranarayanan R. Chapter 8: screening for cervical cancer in developing countries. Vaccine 2006, 24(Suppl. 3):S3/71-S377. Aug 31.
30. D'Souza G., Fakhry C., Sugar E.A., et al. Six-month natural history of oral versus cervical human papillomavirus infection. Int. J. Cancer 2007, 121(1):143-150. Jul 1.
31. D'Souza G., Kreimer A.R., Viscidi R., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 2007, 356(19):1944-1956. May 10.
32. D'Souza G., Agrawal Y., Halpern J., et al. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J. Infect. Dis. 2009, 199(9):1263-1269. May 1.
33. Dunne E.F., Unger E.R., Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA 2007, 297(8):813-819. Feb 28.
34. Ebrahim S.H., McKenna M.T., Marks J.S. Sexual behaviour: related adverse health burden in the United States. Sex. Transm. Infect. 2005, 81(1):38-40. Feb.
35. Elfgren K., Rylander E., Radberg T., et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am. J. Obstet. Gynecol. 2005, 193(3 Pt 1):650-657. Sep.
36. Ferguson R., Ramanakumar A.V., Richardson H., et al. Human leukocyte antigen (HLA)-E and HLA-G polymorphisms in human papillomavirus infection susceptibility and persistence. Hum. Immunol. 2011, 72(4):337-341. Apr.
37. Franceschi S., Herrero R., Clifford G.M., et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int. J. Cancer 2006, 119(11):2677-2684. Dec 1.
38. Franco E.L. Understanding the epidemiology of genital infection with oncogenic and nononcogenic human papillomaviruses: a promising lead for primary prevention of cervical cancer. Cancer Epidemiol. Biomarkers Prev. 1997, 6(10):759-761. Oct.
39. Franco E.L., Villa L.L., Ruiz A., et al. Transmission of cervical human papillomavirus infection by sexual activity: differences between low and high oncogenic risk types. J. Infect. Dis. 1995, 172(3):756-763. Sep.
40. Franco E.L., Villa L.L., Sobrinho J.P., et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J. Infect. Dis. 1999, 180(5):1415-1423. Nov.
41. Franco E.L., Duarte-Franco E., Ferenczy A. Prospects for controlling cervical cancer at the turn of the century. Salud Publica Mex. 2003, 45(Suppl. 3):S367-S375.
42. Franco E.L., Tsu V., Herrero R., et al. Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean. Vaccine 2008, 26(Suppl. 11):L88-L95. Aug 19.
43. Gillison M.L. Current topics in the epidemiology of oral cavity and oropharyngeal cancers. Head Neck 2007, 29(8):779-792. Aug.
44. Gillison M.L. Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination. J. Adolesc. Health 2008, 43(4 Suppl.):S52-S60. Oct.
45. Gillison M.L., D'Souza G., Westra W., et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J. Natl. Cancer Inst. 2008, 100(6):407-420. Mar 19.
46. Gillison M.L., Chaturvedi A.K., Lowy D.R. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008, 113(10 Suppl.):3036-3046. Nov 15.
47. Giuliano A.R., Siegel E.M., Roe D.J., et al. Dietary intake and risk of persistent human papillomavirus (HPV) infection: the Ludwig-McGill HPV natural history study. J. Infect. Dis. 2003, 188(10):1508-1516. Nov 15.
48. Giuliano A.R., Tortolero-Luna G., Ferrer E., et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008, 26(Suppl. 10):K17-K28. Aug 19.
49. Giuliano A.R., Palefsky J.M., Goldstone S., et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N. Engl. J. Med. 2011, 364(5):401-411. Feb 3.
50. Goldie S.J., O'Shea M., Campos N.G., et al. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008, 26(32):4080-4093. Jul 29.
51. Gonzalez P., Hildesheim A., Rodriguez A.C., et al. Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45years. Cancer Epidemiol. Biomarkers Prev. 2010, 19(12):3044-3054. Dec.
52. Goodman M.T., Shvetsov Y.B., McDuffie K., et al. Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV cohort study. J. Infect. Dis. 2008, 197(7):957-966. Apr 1.
53. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367(9518):1247-1255. Apr 15.
54. Heck J.E., Berthiller J., Vaccarella S., et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int. J. Epidemiol. 2010, 39(1):166-181. Feb.
55. Hernandez B.Y., McDuffie K., Zhu X., et al. Anal human papillomavirus infection in women and its relationship with cervical infection. Cancer Epidemiol. Biomarkers Prev. 2005, 14(11 Pt 1):2550-2556. Nov.
56. Hernandez B.Y., Wilkens L.R., Zhu X., et al. Transmission of human papillomavirus in heterosexual couples. Emerg. Infect. Dis. 2008, 14(6):888-894. Jun.
57. Herrero R., Castellsague X., Pawlita M., et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J. Natl. Cancer Inst. 2003, 95(23):1772-1783. Dec 3.
58. Herrero R., Castle P.E., Schiffman M., et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J. Infect. Dis. 2005, 191(11):1796-1807. Jun 1.
59. Hildesheim A., Schiffman M.H., Gravitt P.E., et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J. Infect. Dis. 1994, 169(2):235-240. Feb.
60. Ho G.Y., Burk R.D., Klein S., et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. 1995, 87(18):1365-1371. Sep 20.
61. Ho G.Y., Bierman R., Beardsley L., et al. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 1998, 338(7):423-428. Feb 12.
62. IARC Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 2005.
63. IARC Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 2011.
64. Jemal A., Ward E., Thun M. Declining death rates reflect progress against cancer. PLoS One 2010, 5(3):e9584.
65. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol. Oncol. 2008, 110(3 Suppl. 1):S18-S25. Sep.
66. Kahn J.A., Rosenthal S.L., Succop P.A., et al. Mediators of the association between age of first sexual intercourse and subsequent human papillomavirus infection. Pediatrics 2002, 109(1):E5. Jan.
67. Kitchener H.C., Almonte M., Thomson C., et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009, 10(7):672-682. Jul.
68. Kjaer S.K., van den Brule A.J., Bock J.E., et al. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types?. Cancer Epidemiol. Biomarkers Prev. 1997, 6(10):799-805. Oct.
69. Kjaer S.K., Svare E.I., Worm A.M., et al. Human papillomavirus infection in Danish female sex workers. Decreasing prevalence with age despite continuously high sexual activity. Sex. Transm. Dis. 2000, 27(8):438-445. Sep.
70. Kjaer S.K., van den Brule A.J., Paull G., et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002, 325(7364):572. Sep 14.
71. Kjaer S.K., Munk C., Winther J.F., et al. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol. Biomarkers Prev. 2005, 14(6):1528-1533. Jun.
72. Kotaniemi-Talonen L., Nieminen P., Anttila A., et al. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br. J. Cancer 2005, 93(8):862-867. Oct 17.
73. Koutsky L.A., Galloway D.A., Holmes K.K. Epidemiology of genital human papillomavirus infection. Epidemiol. Rev. 1988, 10:122-163.
74. Koutsky L.A., Holmes K.K., Critchlow C.W., et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med. 1992, 327(18):1272-1278. Oct 29.
75. Kreimer A.R., Clifford G.M., Boyle P., et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol. Biomarkers Prev. 2005, 14(2):467-475. Feb.
76. Lajous M., Mueller N., Cruz-Valdez A., et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol. Biomarkers Prev. 2005, 14(7):1710-1716. Jul.
77. Lazcano-Ponce E., Herrero R., Munoz N., et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int. J. Cancer 2001, 91(3):412-420. Feb 1.
78. Leinonen M., Nieminen P., Kotaniemi-Talonen L., et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J. Natl. Cancer Inst. 2009, 101(23):1612-1623.
79. Li N., Franceschi S., Howell-Jones R., et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int. J. Cancer 2011, 128(4):927-935. Feb 15.
80. Liaw K.L., Glass A.G., Manos M.M., et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J. Natl. Cancer Inst. 1999, 91(11):954-960. Jun 2.
81. Liaw K.L., Hildesheim A., Burk R.D., et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J. Infect. Dis. 2001, 183(1):8-15. Jan 1.
82. Lorincz A.T. Hybrid capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening. J. Obstet. Gynaecol. Res. 1996, 22(6):629-636. Dec.
83. Lorincz A.T., Reid R., Jenson A.B., et al. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet. Gynecol. 1992, 79(3):328-337. Mar.
84. Macaluso M., Demand M.J., Artz L.M., et al. Partner type and condom use. AIDS (London, England) 2000, 14(5):537-546. Mar 31.
85. Maciag P.C., Schlecht N.F., Souza P.S., et al. Polymorphisms of the human leukocyte antigen DRB1 and DQB1 genes and the natural history of human papillomavirus infection. J. Infect. Dis. 2002, 186(2):164-172. Jul 15.
86. Manhart L.E., Koutsky L.A. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex. Transm. Dis. 2002, 29(11):725-735. Nov.
87. Marrazzo J.M., Koutsky L.A., Kiviat N.B., et al. Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women. Am. J. Public Health 2001, 91(6):947-952. Jun.
88. Mayrand M.H., Duarte-Franco E., Rodrigues I., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 2007, 357(16):1579-1588. Oct 18.
89. Mejlhede N., Pedersen B.V., Frisch M., et al. Multiple human papilloma virus types in cervical infections: competition or synergy?. APMIS 2010, 118(5):346-352. May.
90. Mendez F., Munoz N., Posso H., et al. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J. Infect. Dis. 2005, 192(7):1158-1165. Oct 1.
91. Merikukka M., Kaasila M., Namujju P.B., et al. Differences in incidence and co-occurrence of vaccine and non-vaccine human papillomavirus (HPV) types in Finnish population before HPV mass vaccination suggest competitive advantage for HPV33. Int. J. Cancer 2010, 13. Sep.
92. Molano M., Van den Brule A., Plummer M., et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am. J. Epidemiol. 2003, 158(5):486-494. Sep 1.
93. Monk B.J., Tewari K.S. The spectrum and clinical sequelae of human papillomavirus infection. Gynecol. Oncol. 2007, 107(2 Suppl. 1):S6-S13. Nov.
94. Moscicki A.B., Shiboski S., Broering J., et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J. Pediatr. 1998, 132(2):277-284. Feb.
95. Moscicki A.B., Hills N., Shiboski S., et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001, 285(23):2995-3002. Jun 20.
96. Munoz N., Bosch F.X., de Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348(6):518-527. Feb 6.
97. Financing HPV vaccination in developing countries. Lancet 2011, 377(9777):1544. May 7.
98. Nanda K., McCrory D.C., Myers E.R., et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med. 2000, 132(10):810-819. May 16.
99. Naucler P., Ryd W., Tornberg S., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 2007, 357(16):1589-1597. Oct 18.
100. Naucler P., Ryd W., Tornberg S., et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J. Natl. Cancer Inst. 2009, 101(2):88-99. Jan 21.
101. Nielson C.M., Flores R., Harris R.B., et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol. Biomarkers Prev. 2007, 16(6):1107-1114. Jun.
102. Nobbenhuis M.A., Walboomers J.M., Helmerhorst T.J., et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999, 354(9172):20-25. Jul 3.
103. Ostor A.G. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 1993, 12(2):186-192. Apr.
104. Paavonen J., Naud P., Salmeron J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314. Jul 25.
105. Palefsky J.M., Holly E.A., Ralston M.L., et al. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J. Infect. Dis. 2001, 183(3):383-391. Feb 1.
106. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 2006, 118(12):3030-3044. Jun 15.
107. Partridge J.M., Hughes J.P., Feng Q., et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J. Infect. Dis. 2007, 196(8):1128-1136. Oct 15.
108. Peres J. For cancers caused by HPV, two vaccines were just the beginning. J. Natl. Cancer Inst. 2011, 103(5):360-362. Mar 2.
109. Plummer M., Schiffman M., Castle P.E., et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J. Infect. Dis. 2007, 195(11):1582-1589. Jun 1.
110. Ramanakumar A.V., Goncalves O., Richardson H., et al. Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women. BMC Infect. Dis. 2010, 10:326.
111. Remmink A.J., Walboomers J.M., Helmerhorst T.J., et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36months. Int. J. Cancer 1995, 61(3):306-311. May 4.
112. Richardson H., Franco E., Pintos J., et al. Determinants of low-risk and high-risk cervical human papillomavirus infections in Montreal University students. Sex. Transm. Dis. 2000, 27(2):79-86. Feb.
113. Richardson H., Kelsall G., Tellier P., et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol. Biomark. Prev. 2003, 12(6):485-490. Jun.
114. Roberts J.N., Buck C.B., Thompson C.D., et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 2007, 13(7):857-861. Jul.
115. Roberts J.N., Kines R.C., Katki H.A., et al. Effect of pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J. Natl. Cancer Inst. 2011, 103(9):737-743. May 4.
116. Ronco G., Giorgi-Rossi P., Carozzi F., et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35years: results at recruitment for a randomised controlled trial. Lancet Oncol. 2006, 7(7):547-555. Jul.
117. Ronco G., Cuzick J., Pierotti P., et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ 2007, 335(7609):28. Jul 7.
118. Ronco G., Giorgi-Rossi P., Carozzi F., et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J. Natl. Cancer Inst. 2008, 100(7):492-501. Apr 2.
119. Rousseau M.C., Franco E.L., Villa L.L., et al. A cumulative case-control study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections. Cancer Epidemiol. Biomarkers Prev. 2000, 9(5):469-476. May.
120. Rousseau M.C., Pereira J.S., Prado J.C., et al. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J. Infect. Dis. 2001, 184(12):1508-1517. Dec 15.
121. Rousseau M.C., Villa L.L., Costa M.C., et al. Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex. Transm. Dis. 2003, 30(7):581-587. Jul.
122. Sankaranarayanan R., Nene B.M., Shastri S.S., et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 2009, 360(14):1385-1394. Apr 2.
123. Schiffman M., Castle P.E., Jeronimo J., et al. Human papillomavirus and cervical cancer. Lancet 2007, 370(9590):890-907. Sep 8.
124. Schiffman M., Clifford G., Buonaguro F.M. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect. Agent Cancer 2009, 4:8.
125. Schiffman M., Wentzensen N., Wacholder S., et al. Human papillomavirus testing in the prevention of cervical cancer. J. Natl. Cancer Inst. 2011, 103(5):368-383. Mar 2.
126. Schlecht N.F., Kulaga S., Robitaille J., et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001, 286(24):3106-3114. Dec 26.
127. Schlecht N.F., Trevisan A., Duarte-Franco E., et al. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int. J. Cancer 2003, 103(4):519-524. Feb 10.
128. Sellors J.W., Karwalajtys T.L., Kaczorowski J., et al. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 2003, 168(4):421-425. Feb 18.
129. Sherman M.E., Wang S.S., Carreon J., et al. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer 2005, 103(6):1258-1264. Mar 15.
130. Smith J.S., Melendy A., Rana R.K., et al. Age-specific prevalence of infection with human papillomavirus in females: a global review. J. Adolesc. Health 2008, 43(4 Suppl.):S5-S25. Oct, S25 e21-41.
131. Smith J.S., Backes D.M., Hudgens M.G., et al. Prevalence and risk factors of human papillomavirus infection by penile site in uncircumcised Kenyan men. Int. J. Cancer 2010, 126(2):572-577. Jan 15.
132. Smith J.S., Gilbert P.A., Melendy A., et al. Age-specific prevalence of human papillomavirus infection in males: a global review. J. Adolesc. Health 2011, 48(6):540-552. Jun.
133. Sonnex C., Strauss S., Gray J.J. Detection of human papillomavirus DNA on the fingers of patients with genital warts. Sex. Transm. Infect. 1999, 75(5):317-319. Oct.
134. Sundstrom K., Eloranta S., Sparen P., et al. Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix. Cancer Epidemiol. Biomarkers Prev. 2010, 19(10):2469-2478. Oct.
135. Thomas K.K., Hughes J.P., Kuypers J.M., et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J. Infect. Dis. 2000, 182(4):1097-1102. Oct.
136. Tobian A.A., Serwadda D., Quinn T.C., et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N. Engl. J. Med. 2009, 360(13):1298-1309. Mar 26.
137. Tota J., Mahmud S.M., Ferenczy A., et al. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era. Sex. Health 2010, 7(3):376-382. Sep.
138. Tseng C.J., Liang C.C., Soong Y.K., et al. Perinatal transmission of human papillomavirus in infants: relationship between infection rate and mode of delivery. Obstet. Gynecol. 1998, 91(1):92-96. Jan.
139. Vaccarella S., Franceschi S., Snijders P.J., et al. Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol. Biomarkers Prev. 2010, 19(2):503-510. Feb.
140. Vardas E., Giuliano A.R., Goldstone S., et al. External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. J. Infect. Dis. 2011, 203(1):58-65. Jan 1.
141. Vizcaino A.P., Moreno V., Bosch F.X., et al. International trends in the incidence of cervical cancer: I. adenocarcinoma and adenosquamous cell carcinomas. Int. J. Cancer 1998, 75(4):536-545. Feb 9.
142. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189(1):12-19. Sep.
143. Warner L., Newman D.R., Austin H.D., et al. Condom effectiveness for reducing transmission of gonorrhea and chlamydia: the importance of assessing partner infection status. Am. J. Epidemiol. 2004, 159(3):242-251. Feb 1.
144. Wawer M.J., Tobian A.A., Kigozi G., et al. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet 2011, 377(9761):209-218. Jan 15.
145. Weaver B.A., Feng Q., Holmes K.K., et al. Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J. Infect. Dis. 2004, 189(4):677-685. Feb 15.
146. Winer R.L., Lee S.K., Hughes J.P., et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am. J. Epidemiol. 2003, 157(3):218-226. Feb 1.
147. Winer R.L., Hughes J.P., Feng Q., et al. Condom use and the risk of genital human papillomavirus infection in young women. N. Engl. J. Med. 2006, 354(25):2645-2654. Jun 22.
148. Wong, C.A., Berkowitz, Z., Dorell, C.G., et al., in press. Human papillomavirus vaccine uptake among 9- to 17-year-old girls: national health interview survey, 2008. Cancer Jun 20 (Epub ahead of print). doi:10.1002/cncr.26246.
149. Ylitalo N., Josefsson A., Melbye M., et al. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res. 2000, 60(21):6027-6032. Nov 1.